Although we acknowledge the lack of functional validation and the limited size of our patient population, we believe the statistical difference observed between CCR6 expression in adrenal metastases and corresponding primary tumors suggests a role for the CCR6 receptor in the organ orientation of adrenal metastases in lung cancer. Our results support the possibility that circulating CCR6-expressing tumor cells are oriented toward the adrenal gland by the adrenal CCL20 expression in patients with NSCLC.
The work in the Laure Sabatier laboratory was supported by TELINCA (Telomere Research Program of the Institut National du Cancer) and RISC-RAD (Radiosensitivity of Individuals and Susceptibility to Cancer Induced by Ionizing Radiations; contract number FI6R-CT2003-508842). We thank Dr. Fabrizio D'Adda di Fagagna for his interactions and helpful discussions. Christophe Raynaud is a doctoral fellow funded by a CEA (Commissariat à l'Energie Atomique)-Lilly Fellowship.
Clin Lung Cancer. 2010;11(3):187-191. © 2010 CIG Media Group, LP
Cite this: Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer - Medscape - May 01, 2010.